CD47 Inhibitors Drug Market & Clinical Trials Insight 2026, Featuring Adagene, Akeso, ALX Oncology, EpicentRx, ImmuneOncia, ImmuneOnco Biopharma, Phanes Therapeutics, Virtuoso Therapeutics...
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
With over 80 drugs in trials, innovations like bispecific antibodies, combination therapies, and personalized treatment strategies are key opportunities, underpinned by significant corporate R&D investments. Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "CD47 Inhibitors Drug Market Opportunity, Clinical Application by Indications & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. The quest for new cancer treatments has highlighted the CD47 pathway, an immune checkpoint that enables cancer to escape attack by the immune system. CD47 can be called the "don't eat me" signal that cancer cells emit to prevent elimination by macrophages, a key element of the innate immune system. This renders CD47 a very promising therapeutic target for a broad panel of hematologic malignancies and solid tumors. While PD-1/PD-L1 inhibitors have shown significant progress, numerous patients do not respond or become resistant, emphasizing the pressing need for new
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- ALX Oncology to Present at Upcoming Investor ConferencesGlobeNewswire
- ALX Oncology (NASDAQ:ALXO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $4.00 price target on the stock.MarketBeat
- ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
ALXO
Earnings
- 11/7/25 - Miss
ALXO
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/7/25 - Form 10-Q
- ALXO's page on the SEC website